Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
Autores da FMUP
Participantes de fora da FMUP
- MENDONÇA L.U.Í.S.
- NEVES J.S.
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 1071-9164, 1532-8414
- Tipo:
- Article
- Páginas:
- 1181-1182
- Link para outro recurso:
- www.scopus.com
Journal of Cardiac Failure Churchill Livingstone
Documentos
- Não há documentos
Filiações
Keywords
- Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; dapagliflozin; sacubitril plus valsartan; semaglutide; sodium glucose cotransporter 2 inhibitor; vericiguat; glucagon like peptide; semaglutide; adverse outcome; all cause mortality; Article; cardiovascular mortality; chronic kidney failure; drug efficacy; drug safety; estimated glomerular filtration rate; follow up; heart failure; heart failure with reduced ejection fraction; human; kidney disease; kidney function; kidney transplantation; mortality rate; non insulin dependent diabetes mellitus; renal replacement therapy; risk reduction; complication; drug therapy; non insulin dependent diabetes mellitus
Campos de estudo
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Ferreira JP,MENDONÇA LUÍS,NEVES JS. Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?. J. Card. Fail. 2024. 30. (9):p. 1181-1182. IF:6,000. (1).